Czech National Bank Boosts Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Czech National Bank lifted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 5.9% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 18,807 shares of the company's stock after buying an additional 1,052 shares during the period. Czech National Bank's holdings in IDEXX Laboratories were worth $7,898,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of IDXX. Norges Bank purchased a new stake in shares of IDEXX Laboratories during the 4th quarter worth $412,258,000. GAMMA Investing LLC boosted its holdings in IDEXX Laboratories by 59,810.7% during the first quarter. GAMMA Investing LLC now owns 918,431 shares of the company's stock worth $3,856,950,000 after buying an additional 916,898 shares in the last quarter. Flossbach Von Storch SE grew its position in IDEXX Laboratories by 5,439.3% during the fourth quarter. Flossbach Von Storch SE now owns 473,336 shares of the company's stock worth $195,696,000 after buying an additional 464,791 shares during the period. Alyeska Investment Group L.P. acquired a new stake in shares of IDEXX Laboratories during the 4th quarter valued at approximately $156,412,000. Finally, William Blair Investment Management LLC lifted its position in shares of IDEXX Laboratories by 701.6% during the 4th quarter. William Blair Investment Management LLC now owns 422,133 shares of the company's stock valued at $174,527,000 after acquiring an additional 369,471 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on IDXX. Stifel Nicolaus raised their price objective on IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a research note on Monday, May 19th. Piper Sandler lifted their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Morgan Stanley boosted their price objective on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research report on Monday, May 5th. Finally, Wall Street Zen downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Four analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, IDEXX Laboratories has a consensus rating of "Moderate Buy" and an average price target of $536.00.

Insider Buying and Selling

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of the stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total value of $645,548.40. Following the completion of the sale, the director now owns 1,801 shares of the company's stock, valued at $922,724.34. This trade represents a 41.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.98% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Trading Down 0.5%

IDEXX Laboratories stock traded down $2.65 during trading on Thursday, reaching $522.21. The company had a trading volume of 451,494 shares, compared to its average volume of 650,651. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The firm has a market capitalization of $42.00 billion, a price-to-earnings ratio of 48.94, a PEG ratio of 3.41 and a beta of 1.52. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $530.73. The stock's 50 day moving average price is $455.99 and its two-hundred day moving average price is $439.27.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The business had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. During the same period last year, the company posted $2.71 EPS. The business's quarterly revenue was up 3.6% on a year-over-year basis. As a group, equities analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.